Updated figures demonstrating the strength of the Australian regenerative medicine (RM) sector were released at AusBiotech 2019. Over the past two years, the number of cellular therapy or RM companies in Australia has doubled. The number of research institutions involved in RM has increased from more than 30 to more than 45.
The six-page publication reveals how the RM industry is in a healthy growth trajectory and provides an overview of the key industry milestones and activities, as well as highlighting the benefits of partnering with Australia. It was developed by AusBiotech, with the support of its Regenerative Medicine Advisory Group.
Highlights:
In 2018:
- MTPConnect released the Regenerative Medicine: Opportunities for Australia report, in collaboration with AusBiotech and other stakeholders; and
- The CAR-T Cell Therapy (Kymriah) was approved for use by the TGA.
In 2019:
- TGA issues Australia’s first T-cell therapy manufacturing license to Cell Therapies Pty Ltd;
- Federal Government announces $150 million into 10-year Australian Stem Cell Therapies Mission through the Medicine Research Future Fund. Read AusBiotech’s submission to the recent consultation here.
- The Australian Government announced $80 million towards the development of a dedicated CAR-T Cell therapy treatment facility at the Peter MacCallum Cancer Centre (PMCC) in Victoria. The PMCC will also contribute $25 million to create the Centre for Excellence in Cellular Immunotherapy, which will be one of the first dedicated cell therapies treatment facility of its kind in the world.
Read the full six-page publication here.
Also launched at AusBiotech 2019 was the 5th edition of the AusBiotech and NSW Stem Cell Network snapshot, providing profiles of stem cell and RM companies in Australia.